TVTX (Travere Therapeutics, Inc.) Stock Financials & Earnings

TVTXTravere Therapeutics, Inc.

Mkt Cap$3B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$491M

Net Income (TTM)-$50M

EPS (TTM)-$0.60

Free Cash Flow (TTM)$26M

Gross Margin94.2%

Op. Margin-12.8%

Net Margin-10.2%

FCF Margin5.3%

P/S Ratio (TTM)5.5x

P/E Ratio (TTM)—

YoY Rev Growth+110.5%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$57M	$52M	-$80M
Q2 23	$32M	$31M	-$104M
Q3 23	$37M	$36M	-$93M
Q4 23	$45M	$29M	-$83M
Q1 24	$41M	$40M	-$139M
Q2 24	$54M	$42M	-$67M
Q3 24	$63M	$61M	-$56M
Q4 24	$75M	$72M	-$61M
Q1 25	$82M	$77M	-$43M
Q2 25	$114M	$113M	-$13M
Q3 25	$165M	$163M	$25M
Q4 25	$130M	$109M	-$32M

Valuation

Operating Cash Flow

Capital Expenditures

CapEx

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q1 23	$60M	$66M	$6M	—
Q2 23	$66M	$68M	—	—
Q3 23	$61M	$68M	—	—
Q4 23	$59M	$64M	—	—
Q1 24	$115M	$64M	—	—
Q2 24	$54M	$65M	—	—
Q3 24	$52M	$66M	—	—
Q4 24	$62M	$70M	—	—
Q1 25	$47M	$73M	—	—
Q2 25	$49M	$76M	—	—
Q3 25	$52M	$86M	—	—
Q4 25	$58M	—	—	$102M

Revenue Segments

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$161M	$400M	$562M
Q2 23	$71M	$420M	$491M
Q3 23	$144M	$490M	$635M
Q4 23	$58M	$509M	$567M
Q1 24	$43M	$398M	$441M
Q2 24	$32M	$293M	$325M
Q3 24	$36M	$241M	$277M
Q4 24	$59M	$312M	$371M
Q1 25	$62M	$260M	$322M
Q2 25	$75M	$244M	$320M
Q3 25	$111M	$144M	$255M
Q4 25	$93M	$230M	$323M

Shares Outstanding

Revenue Per Employee

Revenue / Employee